9th Ocular Diseases Drug Discovery Conference
Venue: Hilton San Diego Resort & Spa, San Diego, CA, USA
Date: 20 - 21 March, 2017
GTCbio offers comprehensive sponsorship packages for all our meetings, including presentation opportunities, exhibit and booth space, as well as the event delegate list. All our packages can be customized to meet your company's budget. For information, please contact us.
GTCbio encourages attendees to showcase their research at the conference by presenting a poster. The top 2-3 submitted posters will also be selected to give short oral presentations as part of the meeting program. Abstracts will be accepted until December 6, 2016; slots fill up quickly so submit yours online ASAP!

Dear Colleague,

The 9th Ocular Diseases Drug Discovery Conference is taking place on March 20-21, 2017 in San Diego, CA. We are excited to have top representatives from the industry and academic sectors to discuss technologies and targets that are continually changing the way ocular diseases are treated. Drug delivery is always improving as we look at for better methods to penetrate anterior and poster segments of the eye. Successes in gene therapy and regenerative medicine are proving to be interesting approaches to discuss in detail pre-clinically and clinically. We are gathering leading scientists, researchers, and experts to discuss and collaborate on combating and curing age-related macular degeneration (AMD), dry eye, glaucoma, diabetic macular edema (DME), and other ocular diseases.

We hope to see you there!

Best regards,

The 2017 Advisory Committee


What Past Delegates Said About the Event:

“One of the must attend ophthalmic meetings to learn and debate on the about the latest innovations in ocular diseases, including both drug and drug delivery developments. Great opportunity for networking, Q&A and interaction with the speaker”
-Michael O’Rourke, President & CEO, GrayBug Inc.

"As a relative newcomer to the field, I really appreciated how the conference provided exposure to a range of current innovations in ophthalmology, in an intimate setting that fostered open dialogue and meaningful networking."
-Leah Makley, Founder & CSO, ViewPoint Therapeutics

"GTC's Ocular Disease and Drug Development meeting was perfectly orchestrated, providing a nice balance of science and innovation with targeted networking opportunities in the ophthalmology field."
- Christopher Stanley, Chief Business Officer, RxGen Inc.

"This was a great learning experience, both for some fundamental concepts and for the latest developments in ocular drug development."
-Christopher Bode, Ph.D. VP Scientific & Corporate Communications, Absorption Systems


ocular-diseases-drug-discovery Overview